Patent · US Active

Anti-CTLA4 antibodies and uses thereof

US11034764B2 · kind B2 · utility

1Cited by
0References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 11, 2020
Grant dateJun 15, 2021
Priority date—
Expiry dateMar 11, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.